<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">RSC Adv</journal-id><journal-id journal-id-type="iso-abbrev">RSC Adv</journal-id><journal-id journal-id-type="publisher-id">RA</journal-id><journal-id journal-id-type="coden">RSCACL</journal-id><journal-title-group><journal-title>RSC Advances</journal-title></journal-title-group><issn pub-type="epub">2046-2069</issn><publisher><publisher-name>The Royal Society of Chemistry</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12093506</article-id><article-id pub-id-type="publisher-id">d5ra01971k</article-id><article-id pub-id-type="doi">10.1039/d5ra01971k</article-id><article-categories><subj-group subj-group-type="heading"><subject>Chemistry</subject></subj-group></article-categories><title-group><article-title>Synthesis, characterization, and <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in silico</italic> &#x003b1;-glucosidase inhibitory evolution of novel <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives<xref rid="fn1" ref-type="fn">&#x02020;</xref></article-title><fn-group><fn id="fn1"><label>&#x02020;</label><p>Electronic supplementary information (ESI) available. See DOI: <uri xlink:href="https://doi.org/10.1039/d5ra01971k">https://doi.org/10.1039/d5ra01971k</uri></p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mudireddy</surname><given-names>Ram Reddy</given-names></name><xref rid="affa" ref-type="aff">a</xref><xref rid="affb" ref-type="aff">b</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gundla</surname><given-names>Rambabu</given-names></name><xref rid="affa" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Shaik</surname><given-names>Baji Baba</given-names></name><xref rid="affc" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Bodapati</surname><given-names>Anoop</given-names></name><xref rid="affd" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Mahesh</surname><given-names>Panasa</given-names></name><xref rid="affa" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Naidu</surname><given-names>Shiva Sravan</given-names></name><xref rid="affe" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Tirumalasetti</surname><given-names>Damodar</given-names></name><xref rid="afff" ref-type="aff">f</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Katari</surname><given-names>Naresh Kumar</given-names></name><xref rid="affc" ref-type="aff">c</xref></contrib><aff id="affa">
<label>a</label>
<institution>Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University) Hyderabad</institution>
<state>Telangana 502 329</state>
<country>India</country>
<email>rgundla@gitam.edu</email>
</aff><aff id="affb">
<label>b</label>
<institution>B.V.Raju Institute of Technology</institution>
<addr-line>Vishnupur, Narsapur, Medak Dist</addr-line>
<state>Telangana 502313</state>
<country>India</country>
</aff><aff id="affc">
<label>c</label>
<institution>School of Chemistry &#x00026; Physics, College of Agriculture, Engineering &#x00026; Science, University of KwaZulu-Natal</institution>
<addr-line>Westville Campus, P Bag X 54001</addr-line>
<city>Durban 4000</city>
<country>South Africa</country>
<email>KatariN@ukzn.ac.za</email>
</aff><aff id="affd">
<label>d</label>
<institution>Analytical Research &#x00026; Development, Hikma Pharmaceuticals USA Inc</institution>
<city>Columbus</city>
<state>Ohio 43228</state>
<country>USA</country>
</aff><aff id="affe">
<label>e</label>
<institution>R&#x00026;D, Vertex Pharmaceuticals</institution>
<addr-line>316 Northern Avenue</addr-line>
<city>Boston</city>
<state>MA 02210</state>
<country>USA</country>
</aff><aff id="afff">
<label>f</label>
<institution>Department of Chemistry, University of Pennsylvania</institution>
<addr-line>New Town</addr-line>
<state>PA 18940</state>
<country>USA</country>
</aff></contrib-group><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-05-21"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2025-05-21"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>15</volume><issue>22</issue><fpage>17118</fpage><lpage>17129</lpage><history><date date-type="received" iso-8601-date="2025-03-20"><day>20</day><month>3</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-04-24"><day>24</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>This journal is &#x000a9; The Royal Society of Chemistry</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Royal Society of Chemistry</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-05-21">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p>This article is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution 3.0 Unported Licence</ext-link>. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.</license-p></license></permissions><abstract><p>To discover potential &#x003b1;-glucosidase inhibitory agents, a new series of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives were designed and synthesized as &#x003b1;-glucosidase inhibitors. The newly synthesized compounds were characterized using <sup>1</sup>H, <sup>13</sup>C NMR, and mass spectroscopy analysis and evaluated for their <italic toggle="yes">in vitro</italic> &#x003b1;-glucosidase inhibitory effects. All the tested compounds displayed significant &#x003b1;-glucosidase inhibitory activity compared to the standard drug acarbose. Among all, compounds 7b, 7d and 6g exhibited the strongest inhibition with IC<sub>50</sub> values of 14.48 nmol, 18.88 nmol and 28.51 nmol, respectively. Molecular docking analysis was conducted to identify the important binding interactions responsible for inhibition activity of a-glucosidase. The compounds 7b and 7d exhibit the highest docking energies, with same value of &#x02212;10.1 kcal mol<sup>&#x02212;1</sup> with crucial hydrogen bonding interactions with HIS:280 and ASN:415, respectively. Furthermore, computational drug likeness/ADME/toxicity analysis was conducted on the compounds, which indicated that these compounds exhibit drug-like properties and possess favourable ADME and toxicity profiles.</p></abstract><abstract abstract-type="toc"><p>To discover potential &#x003b1;-glucosidase inhibitory agents, a new series of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives were designed and synthesized as &#x003b1;-glucosidase inhibitors.<graphic xlink:href="d5ra01971k-ga.jpg" id="ga" position="float"/></p></abstract><funding-group><award-group><funding-source>
<institution-wrap><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution><institution-id institution-id-type="doi">10.13039/501100001407</institution-id></institution-wrap>
</funding-source><award-id>BT/AIR01566/PACE-27/22</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>Biotechnology Industry Research Assistance Council</institution><institution-id institution-id-type="doi">10.13039/501100014825</institution-id></institution-wrap>
</funding-source><award-id>BT/AIR01566/PACE-27/22</award-id></award-group></funding-group><counts><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pubstatus</meta-name><meta-value>Paginated Article</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>A well-known metabolic disease, diabetes mellitus, has emerged as a major public health concern in the modern era owing to the devastating consequences it can have on an individual's wellness over time.<sup><xref rid="cit1" ref-type="bibr">1,2</xref></sup> Specifically, type 2 diabetes (T2DM) accounts for the most encountered form of diabetes.<sup><xref rid="cit3" ref-type="bibr">3,4</xref></sup> Major risk factors for developing diabetes include abnormalities in glucose metabolism.<sup><xref rid="cit5" ref-type="bibr">5</xref></sup> The hallmark of type 2 diabetes is an irregular rise in blood glucose levels.<sup><xref rid="cit6" ref-type="bibr">6,7</xref></sup> Acute hyperglycaemia damages blood vessels by acting directly on the vascular endothelium; this damages the patient's quality of life and eventually leads to heart attacks, strokes, retinopathy, and coronary heart disease.<sup><xref rid="cit8" ref-type="bibr">8,9</xref></sup> Currently, the US FDA has approved five main classes of oral antidiabetic drugs: biguanides, thiazolidinediones, sulfonylureas, meglitinides and &#x003b1;-glucosidase inhibitors.<sup><xref rid="cit10" ref-type="bibr">10&#x02013;12</xref></sup> Unfortunately, some patients experience intolerable adverse effects from these drugs, while others see their effectiveness wane with time.<sup><xref rid="cit13" ref-type="bibr">13,14</xref></sup> Consequently, there has been and will be immense interest in the development for novel anti-diabetic drugs. Among these drugs, oral anti-diabetic drugs such as &#x003b1;-glucosidase inhibitors reduce postprandial hyperglycemia by inhibiting the enzyme a-glucosidase, which is responsible for the carbohydrate's degradation.<sup><xref rid="cit15" ref-type="bibr">15&#x02013;17</xref></sup> The Third Asia-Pacific Region Diabetes Treatment Guidelines have recommended &#x003b1;-glucosidase inhibitors as the first line for decreasing postprandial hyperglycemia due to their several advantages.<sup><xref rid="cit18" ref-type="bibr">18</xref></sup></p><p>&#x003b1;-Glucosidase is an essential enzyme in the amylase family, significantly contributing to carbohydrate metabolism in organisms.<sup><xref rid="cit19" ref-type="bibr">19&#x02013;21</xref></sup> So, by limiting &#x003b1;-glucosidase activity, intestinal glycolysis can be diminished, leading to a reduction in postprandial hyperglycemia.<sup><xref rid="cit22" ref-type="bibr">22,23</xref></sup> At now, &#x003b1;-glucosidase inhibitors, namely acarbose, voglibose, and miglitol (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>), have been developed in the clinical treatment of T2DM.<sup><xref rid="cit24" ref-type="bibr">24,25</xref></sup> However, prolonged use of these drugs may result in gastrointestinal adverse effects.<sup><xref rid="cit26" ref-type="bibr">26&#x02013;29</xref></sup> Therefore, it is essential to develop novel &#x003b1;-glucosidase inhibitors to tackle diabetes. To date, many research groups are developed novel &#x003b1;-glucosidase inhibitors and some of these compounds are under preclinical evaluation.<sup><xref rid="cit30" ref-type="bibr">30&#x02013;34</xref></sup></p><fig position="float" id="fig1"><label>Fig. 1</label><caption><title>Rationale design of targeted compounds 6a&#x02013;g and 7a&#x02013;g.</title></caption><graphic xlink:href="d5ra01971k-f1" position="float"/></fig><p>Cinnamic acid, a significant component of <italic toggle="yes">Cinnamomum cassia Presl</italic>, exhibits several biological activities,<sup><xref rid="cit35" ref-type="bibr">35</xref></sup> including anticancer,<sup><xref rid="cit36" ref-type="bibr">36&#x02013;42</xref></sup> antioxidative,<sup><xref rid="cit43" ref-type="bibr">43</xref></sup> cardioprotective,<sup><xref rid="cit44" ref-type="bibr">44,45</xref></sup> antibacterial<sup><xref rid="cit46" ref-type="bibr">46,47</xref></sup> and antidiabetic<sup><xref rid="cit48" ref-type="bibr">48,49</xref></sup> properties. The structural alteration of cinnamic acid is garnering increasing attention to generate more potent molecules.<sup><xref rid="cit36" ref-type="bibr">36</xref></sup> Cinnamic acid derivatives (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) and cinnamic acid ester derivatives (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) found to have significant inhibitory activity against &#x003b1;-glucosidase. Chun <italic toggle="yes">et al.</italic> reported twenty novel cinnamic acid magnolol derivatives and screened for their anti-hyperglycaemic potency (I, IC<sub>50</sub>: 5.11 &#x003bc;M).<sup><xref rid="cit50" ref-type="bibr">50</xref></sup> Siva Prasad <italic toggle="yes">et al.</italic> reported novel deacetylsarmentamide derivatives (II) and evaluated for their <italic toggle="yes">in vitro</italic> &#x003b1;-glucosidase inhibitory potency with an excellent result.<sup><xref rid="cit51" ref-type="bibr">51</xref></sup></p><p>On the other hand, hydrazine's (III &#x00026; IV, <xref rid="fig1" ref-type="fig">Fig. 1</xref>) bonds are prevalent in bioactive and drug candidates and emerged as a favourable ligand in drug discovery because of their unique properties, which include polarity, protein binding, and the proton exchange rate.<sup><xref rid="cit52" ref-type="bibr">52</xref></sup> Similarly, compounds with phenyl rings were evaluated for their &#x003b1;-glucosidase inhibitory properties and identified as potential lead agents for type II diabetes mellitus (V &#x00026; VI, <xref rid="fig1" ref-type="fig">Fig. 1</xref>).<sup><xref rid="cit50" ref-type="bibr">50,53</xref></sup> Taha <italic toggle="yes">et al.</italic> described several compounds containing fluorine atoms linked to the benzene ring, demonstrating significant &#x003b1;-glucosidase inhibitory potential, and demonstrated that the fluorine group influences the potency of the compounds.<sup><xref rid="cit54" ref-type="bibr">54</xref></sup></p><p>The molecular hybridisation strategy involves the combination of two or more pharmacophores into a single molecule to enhance pharmacological activity.<sup><xref rid="cit55" ref-type="bibr">55,56</xref></sup> Following the analysis of marketed drugs and prior research in the synthesis of &#x003b1;-glucosidase inhibitors derived from cinnamic acid derivatives, hydrazone and fluorophenyls, we fused these compounds into a single molecule to develop a series of novel &#x003b1;-glucosidase inhibitors (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p></sec><sec><label>2</label><title>Results and discussion</title><sec><label>2.1.</label><title>Chemistry</title><p>The final derivatives 6a&#x02013;g and 7a&#x02013;g were prepared by using conventional synthesis route as depicted in <xref rid="sch1" ref-type="fig">Scheme 1</xref>. The esterification of commercially available substituted phenyl acetic acid in methanol and catalytic amount of sulfuric acid at 60&#x02013;70 &#x000b0;C to yielded corresponding methyl ester (2a &#x00026; 2b). Compound 2a &#x00026; 2b was alkylated with cyclopentyl bromide in presence of potassium <italic toggle="yes">tert</italic>-butoxide in DMF solvent offered substituted methyl 2-cyclopentyl-2-phenylacetate (3a &#x00026; 3b). Methyl ester was converted to hydrazide with 98% hydrazine hydrate and ethanol at reflux temperature to give substituted 2-cyclopentyl-2-phenylacetohydrazide (4a &#x00026; 4b) with appreciable yield. The key intermediates (4a &#x00026; 4b) was treated with different substituted cinnamic acids to yielded the <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives. The structures of these derivatives were characterized by using IR, <sup>1</sup>H, <sup>13</sup>C NMR and mass spectroscopy analysis.</p><fig position="float" id="sch1" fig-type="scheme"><label>Scheme 1</label><caption><title>Reagents and conditions: (a) sulfuric acid, methanol, 60&#x02013;70 &#x000b0;C, yield 95%; (b) potassium <italic toggle="yes">tert</italic>-butoxide, bromo cyclopentane, DMF, 20&#x02013;30 &#x000b0;C, yield 86%; (c) 98% hydrazine hydride, ethanol, reflux 70 &#x000b0;C, yield 90%; (d) HATU, DIPERA, DMF, rt, 16 h.</title></caption><graphic xlink:href="d5ra01971k-s1" position="float"/></fig></sec><sec><label>2.2.</label><title>&#x003b1;-Glucosidase inhibitory assay</title><p>All the final compound 6a&#x02013;g and 7a&#x02013;g were evaluated for their <italic toggle="yes">in vitro</italic> &#x003b1;-glucosidase inhibitory activity. The results were displayed in <xref rid="tab1" ref-type="table">Table 1</xref>. The results displayed that fluoro substitution of phenyl ring A (7a&#x02013;g) exhibited potential activity compared to unsubstituted phenyl ring A (6a&#x02013;g). The structure&#x02013;activity relationship (SAR) was investigated based on the nature and locations of substitutions on the phenyl rings A and B of the <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide system. The &#x003b1;-glucosidase activities of all synthesized <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide-based candidates, specifically compounds 6a&#x02013;g and 7a&#x02013;g, were superior (IC<sub>50</sub> = 14.48 to 232.72 nmol) in comparison to the standard acarbose (IC<sub>50</sub> = 35.91 nmol). The unsubstituted phenyl group (6a and 7a) shows the moderate inhibition with an IC<sub>50</sub> of 79.75 and 85.16 nmol, suggesting that the unsubstituted phenyl ring does not have much effective in key interactions within the enzyme's active site. Among all (7a&#x02013;g), The most potent compound 7b (IC<sub>50</sub> = 14.48 nmol) containing electron-withdrawing groups (2,4,5-trifluro) on ring A and electron donating (para-methyl) on ring B found to be increased inhibition and most promising &#x003b1;-glucosidase inhibitor among all the synthetic derivatives due to better interaction with the active pockets of enzymes. Furthermore, compound 7d (IC<sub>50</sub> = 18.88 nmol) with <italic toggle="yes">m</italic>-Cl substitution on ring B and a 2,4,5-trifluro substituent on aromatic ring A showed better inhibitory activity as compared to the standard acarbose (IC<sub>50</sub> = 35.91 nmol). Halogenated substituent 4-bromophenyl (7c) and 3-bromophenyl (7f) displayed moderate activity (IC<sub>50</sub>: 49.34 and 33.22 nmol), indicating that bromo substitutions do not enhance binding affinity for &#x003b1;-glucosidase inhibition. A considerable a-glucosidase inhibition was observed by 7g, with an IC<sub>50</sub> of 54.78 nmol. However, simple aromatic ring substrate (7a) exhibited the moderate inhibition. Compound 7e, introducing a methoxy substituent at <italic toggle="yes">para</italic> position have no effect on inhibition.</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><title>&#x003b1;-Glucosidase inhibition of final derivatives 6a&#x02013;g and 7a&#x02013;g</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">S. no</th><th rowspan="1" colspan="1">R</th><th rowspan="1" colspan="1">R<sub>1</sub></th><th rowspan="1" colspan="1">Compound code</th><th rowspan="1" colspan="1">IC<sub>50</sub> (nmol)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">6a</td><td rowspan="1" colspan="1">79.75</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2-Br</td><td rowspan="1" colspan="1">6b</td><td rowspan="1" colspan="1">104.44</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">3-Br</td><td rowspan="1" colspan="1">6c</td><td rowspan="1" colspan="1">
<bold>46.80</bold>
</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">4-Br</td><td rowspan="1" colspan="1">6d</td><td rowspan="1" colspan="1">64.80</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">4-CH<sub>3</sub></td><td rowspan="1" colspan="1">6e</td><td rowspan="1" colspan="1">232.72</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">4-F</td><td rowspan="1" colspan="1">6f</td><td rowspan="1" colspan="1">No inhibition</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">3-NO<sub>2</sub></td><td rowspan="1" colspan="1">6g</td><td rowspan="1" colspan="1">
<bold>28.51</bold>
</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">7a</td><td rowspan="1" colspan="1">85.16</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">4-CH<sub>3</sub></td><td rowspan="1" colspan="1">7b</td><td rowspan="1" colspan="1">
<bold>14.48</bold>
</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">4-Br</td><td rowspan="1" colspan="1">7c</td><td rowspan="1" colspan="1">49.34</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">3-Cl</td><td rowspan="1" colspan="1">7d</td><td rowspan="1" colspan="1">
<bold>18.88</bold>
</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">4-OCH<sub>3</sub></td><td rowspan="1" colspan="1">7e</td><td rowspan="1" colspan="1">No inhibition</td></tr><tr><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">3-Br</td><td rowspan="1" colspan="1">7f</td><td rowspan="1" colspan="1">33.22</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">2,4,5-Trifluro</td><td rowspan="1" colspan="1">3-NO<sub>2</sub></td><td rowspan="1" colspan="1">7g</td><td rowspan="1" colspan="1">54.78</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Acarbose</td><td rowspan="1" colspan="1">35.91</td></tr></tbody></table></table-wrap><p>In the series of 6a&#x02013;g, Compound 6c and 6d had significant inhibition against &#x003b1;-Glucosidase with an IC<sub>50</sub> of 46.80 and 64.80 nmol, respectively. This indicates that bromo substitution had considerable effect in both cases (6 and 7). Compound 6a, which is simple aromatic group exhibited an IC<sub>50</sub> value of 79.75 nmol. Further, substituting the R<sub>1</sub> position to a nitro group at <italic toggle="yes">meta</italic> position in 6g enhanced the inhibition (IC<sub>50</sub> = 28.51 nmol). Compound 6b and 6e showed moderate inhibition. However, 6f and 7e had no inhibition effect. From the results, it could be concluded that the introduction of methyl and halogen in the <italic toggle="yes">para</italic> or <italic toggle="yes">ortho</italic> position of phenyl ring leads to an improved increase of the inhibitory activity. The SAR analysis of final derivatives was shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p><fig position="float" id="fig2"><label>Fig. 2</label><caption><title>SAR of the synthesized target compounds 6a&#x02013;g and 7a&#x02013;g.</title></caption><graphic xlink:href="d5ra01971k-f2" position="float"/></fig></sec><sec><label>2.3.</label><title>Docking studies</title><p>Molecular docking is an effective technique for elucidating the interaction mechanism between a ligand and its receptor, as well as forecasting the potential binding site of the ligand.<sup><xref rid="cit57" ref-type="bibr">57,58</xref></sup> To further improve and confirm the inhibitory profile synthesized compounds, a thorough screening procedure was carried out using AutoDock Vina (RSC PDD:<uri>3WY1</uri>) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). Among the compounds that were docked, 7b, and7d had the highest docking energy, whereas 6c had the lowest docking energy. Hybrid 7b and 7d sticks an efficient conformation in the &#x003b1;-glucosidase binding pocket. Compound 7b had a docking energy of &#x02212;10.1 kcal mol<sup>&#x02212;1</sup>. Whereas, compounds 7d and 7a exhibited docking energies of &#x02212;10.1 kcal mol<sup>&#x02212;1</sup> and &#x02212;9.9 kcal mol<sup>&#x02212;1</sup>, respectively. The 7b formed a conventional hydrogen bonding with HIS:280 and ASN:415. The 7d compound forms conventional hydrogen bonds with HIS:280 and ASN:415. The compound 6c exhibited the lowest docking energy, with &#x02212;8.9 kcal mol<sup>&#x02212;1</sup>. In addition, the presence of a conventional hydrogen bond with PRO:312 and ARG:315 were found. These findings were supported to the <italic toggle="yes">in vitro</italic> assay.</p><fig position="float" id="fig3"><label>Fig. 3</label><caption><title>3D &#x00026; 2D Ligand interaction diagrams for docking compounds A: 7b; B: 7d (PDB ID: <uri>3WY1</uri>).</title></caption><graphic xlink:href="d5ra01971k-f3" position="float"/></fig></sec><sec><label>2.4.</label><title>Evaluation of physico-chemical properties</title><p>Literature review indicated that drugs with lower molecular weights and more lipophilicity can be absorbed and excreted <italic toggle="yes">via</italic> para cellular and trans cellular routes with greater ease. Possible side effects include mild toxicity and increase renal excretion. A molecule with drug-like qualities (DLM) can be precisely characterized using the rule of five (RO5).<sup><xref rid="cit59" ref-type="bibr">59</xref></sup> The pharmacokinetic characteristics of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives 6a&#x02013;g and 7a&#x02013;g, such as permeability of the blood&#x02013;brain barrier (BBB) and gastrointestinal absorption (GIA) have also calculated (<xref rid="tab2" ref-type="table">Table 2</xref>). As illustrated in <xref rid="fig4" ref-type="fig">Fig. 4</xref> and <xref rid="fig5" ref-type="fig">5</xref>, the intestinal or brain estimated permeation technique (BOILED Egg) was computed using the lipophilicity, indicated by the WLOGP, and the topological polar surface area (TPSA). All molecules are expected to be inside the white ellipse and grey region. This implies that certain substances may exhibit poorer BBB properties but superior GIA. All drugs whose ability to transport out of the Central Nervous System (CNS) is dependent on <italic toggle="yes">P</italic>-glycoprotein (PGP).<sup><xref rid="cit60" ref-type="bibr">60,61</xref></sup> Compounds 7b and 7d have the highest docking energy with &#x02212;10.1 kcal mol<sup>&#x02212;1</sup> and &#x02212;10.1 kcal mol<sup>&#x02212;1</sup>.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><title>Physico-chemical and pharmacokinetic properties of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives 6a&#x02013;g and 7a&#x02013;g</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Compound</th><th colspan="10" rowspan="1">Physico-chemical properties</th><th colspan="3" rowspan="1">Pharmacokinetic properties</th></tr><tr><th rowspan="1" colspan="1">MW (g mol<sup>&#x02212;1</sup>)</th><th rowspan="1" colspan="1">HA</th><th rowspan="1" colspan="1">AHA</th><th rowspan="1" colspan="1">RBs</th><th rowspan="1" colspan="1">HBA</th><th rowspan="1" colspan="1">HBD</th><th rowspan="1" colspan="1">MR</th><th rowspan="1" colspan="1">TPSA</th><th rowspan="1" colspan="1">iLOGP</th><th rowspan="1" colspan="1">Violation</th><th rowspan="1" colspan="1">GI absorption</th><th rowspan="1" colspan="1">BBB permeant</th><th rowspan="1" colspan="1">PgP substrate</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">6a</td><td align="char" char="." rowspan="1" colspan="1">348.44</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">103.37</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.13</td><td align="char" char="." rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6b</td><td align="char" char="." rowspan="1" colspan="1">427.33</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">111.07</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.15</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6c</td><td align="char" char="." rowspan="1" colspan="1">427.33</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">111.07</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">2.88</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6d</td><td align="char" char="." rowspan="1" colspan="1">427.33</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">11.07</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.15</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6e</td><td align="char" char="." rowspan="1" colspan="1">362.46</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">108.33</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">2.97</td><td align="char" char="." rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6f</td><td align="char" char="." rowspan="1" colspan="1">366.43</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">103.32</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.18</td><td align="char" char="." rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">6g</td><td align="char" char="." rowspan="1" colspan="1">393.44</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">112.19</td><td align="char" char="." rowspan="1" colspan="1">104.02</td><td align="char" char="." rowspan="1" colspan="1">2.77</td><td align="char" char="." rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7a</td><td align="char" char="." rowspan="1" colspan="1">402.41</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">103.24</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.24</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7b</td><td align="char" char="." rowspan="1" colspan="1">416.44</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">108.21</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.81</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7c</td><td align="char" char="." rowspan="1" colspan="1">481.31</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">110.94</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.37</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7d</td><td align="char" char="." rowspan="1" colspan="1">427.33</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">111.07</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.15</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7e</td><td align="char" char="." rowspan="1" colspan="1">432.44</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">109.43</td><td align="char" char="." rowspan="1" colspan="1">67.43</td><td align="char" char="." rowspan="1" colspan="1">3.65</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7f</td><td align="char" char="." rowspan="1" colspan="1">481.31</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">110.94</td><td align="char" char="." rowspan="1" colspan="1">58.20</td><td align="char" char="." rowspan="1" colspan="1">3.76</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">7g</td><td align="char" char="." rowspan="1" colspan="1">447.41</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">112.06</td><td align="char" char="." rowspan="1" colspan="1">104.02</td><td align="char" char="." rowspan="1" colspan="1">3.03</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap><fig position="float" id="fig4"><label>Fig. 4</label><caption><title>Boiled egg of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives.</title></caption><graphic xlink:href="d5ra01971k-f4" position="float"/></fig><fig position="float" id="fig5"><label>Fig. 5</label><caption><title>3D representation and web representation of physico-chemical properties of molecule 7b &#x00026; 7d.</title></caption><graphic xlink:href="d5ra01971k-f5" position="float"/></fig></sec></sec><sec><label>3</label><title>Conclusion</title><p>In conclusion, we have synthesized a new series of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives in moderate to excellent yields and characterized by using FT-IT, <sup>1</sup>H NMR, <sup>13</sup>C NMR and HRMS spectral analysis. Thereafter, the target compounds 6a&#x02013;g and 7a&#x02013;g were assessed for <italic toggle="yes">in vitro</italic> activity in inhibiting &#x003b1;-glucosidase. Most of the synthesized compounds exhibited &#x003b1;-glucosidase inhibitory potency with IC<sub>50</sub> values ranging from IC<sub>50</sub> of 14.48 to 232.72 nmol as compared to standard acarbose (IC<sub>50</sub> = 35.91 nmol). Compounds 7b and 7d showed the highest potency with IC<sub>50</sub> values of 14.48 and 18.88 &#x003bc;M, respectively, as compared to standard acarbose, followed by 6g and 7f with IC<sub>50</sub> values of 28.51 and 33.22 nmol, respectively. SAR of synthesized target hybrids were established. SAR indicated that compounds containing halogen and methyl substituents on the phenyl ring of cinnamohydrazide exhibited promising &#x003b1;-glucosidase as compared to those with electron-withdrawing groups. Molecular docking results agreed with <italic toggle="yes">in vitro</italic> biological assay data by forming key conventional hydrogen bonding interactions with HIS:280 and ASN:415 within the &#x003b1;-glucosidase binding pocket. Further, all the novel compounds are under druglike and conform the rules of ADME and toxicity profile. In summary, this study has identified a new family of <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives that could serve as lead compounds for the development of novel &#x003b1;-glucosidase inhibitors.</p></sec><sec><label>4</label><title>Experimental section</title><sec><label>4.1.</label><title>General information</title><sec><label>4.1.1</label><title>Materials</title><p>Bromo cyclopentane, potassium <italic toggle="yes">tert</italic>-butoxide (Avra Synthesis/Afa-Aesar, India), substituted phenylacetic acid (Sigma-Aldrich, India), various substituted cinnamic acid derivatives (TCI, BLD-Pharma, India), sulfuric acid (Finar, India), HPLC-grade DMF, methanol and ethanol (Sigma-Aldrich, India), HATU (Sigma-Aldrich, India).</p></sec><sec><label>4.1.2</label><title>Instrumentation</title><p>FT-IR spectra obtained on Bruker instrument by using spectra manager software. Sample was prepared by taking 3&#x02013;5 mg of compound on 250&#x02013;300 mg of KBr salt. Advance &#x02013; III HD Bruker 300 &#x00026; 500 MHz NMR spectrometer (Bruker Corporation, Billerica, Massachusetts, USA) was used to record <sup>1</sup>H &#x00026; <sup>13</sup>C NMR spectra with CDCl<sub>3</sub> and DMSO-<italic toggle="yes">d</italic><sub>6</sub> as solvents. Chemical shifts are presented in parts per million, downfield from Tetramethyl silane as internal standard. High resolution mass spectrometry spectra (HRMS) were recorded by using the ESI technique, positive mode, capillary 4500, 0.4 bar, dry gas 4.0 L min<sup>&#x02212;1</sup>. Solvents and reagents were used directly from the manufacturer or purified when required by standard procedures.</p></sec></sec><sec><label>4.2.</label><title>Chemistry</title><sec><label>4.2.1</label><title>Synthesis of substituted phenylacetic acid methyl ester (2a &#x00026; 2b)</title><p>Substituted phenylacetic acid methyl ester was synthesized by reacting phenylacetic acid (40 g, 1.0 eq.) with sulfuric acid (0.1 vol.) in methanol (10 vol.) medium at 60&#x02013;70 &#x000b0;C to give substituted phenylacetic acid methyl ester.</p><sec><label>4.2.1.1</label><title>Methyl 2-(2,4,5-trifluorophenyl)acetate (2b)</title><p>Liquid mass: yield 25 g, 94%, <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 7.16&#x02013;7.08 (m, 1H), 6.97&#x02013;6.89 (m, 1H), 3.72 (s, 3H), 3.61 (s, 2H). HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>9</sub>H<sub>7</sub>F<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 204.15 [M + H]<sup>+</sup>, found 203.</p></sec></sec><sec><label>4.2.2</label><title>Synthesis of substituted methyl-2-cyclopentyl-2-phenylacetate (3a &#x00026; 3b)</title><p>To a solution of phenylacetic acid methyl ester (20 g, 1.0 eq.) in DMF (5 vol.) at 20&#x02013;30 &#x000b0;C, potassium <italic toggle="yes">tert</italic>-butoxide (26.9 g, 1.8 eq.) was added in small portions under nitrogen atmosphere over a period of 20&#x02013;30 min at 20&#x02013;30 &#x000b0;C. After completion of addition the reaction mass was allowed to be stirred at 20&#x02013;30 &#x000b0;C for 60 min. There after bromo cyclopentane (23.85 g, 1.2 eq.) in 3 vol of DMF was added to the reaction mass at 20&#x02013;30 &#x000b0;C over a period of 30&#x02013;40 min under nitrogen atmosphere. After completion of addition, the reaction mixture was allowed to stir at 20&#x02013;30 &#x000b0;C for 16 h. The completion of reaction was monitored by using TLC, after completion of the reaction, cold water was added followed by ethyl acetate, and the organic layer was separated. The aqueous layer was again extracted with ethyl acetate (3 &#x000d7; 20 mL). The combined organic layers were washed with water and dried over sodium sulphate and evaporated under vacuum at temperature below 50 &#x000b0;C to obtain the substitutes methyl-2-cyclopentyl-2-phenylacetate (3a and 3b).</p><sec><label>4.2.2.1</label><title>Methyl 2-cyclopentyl-2-phenylacetate (3a)</title><p>Liquid mass: yield 25 g, 86%. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 7.32&#x02013;7.23 (m, 5H), 3.57 (s, 3H), 3.38&#x02013;3.35 (d, <italic toggle="yes">J</italic> = 11.1 Hz 1H), 2.50&#x02013;2.42 (m, 1H), 1.83&#x02013;1.74 (m, 1H), 1.65&#x02013;1.13 (m, 6H), 1.03&#x02013;0.94 (m, 1H). HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>14</sub>H<sub>18</sub>O<sub>2</sub>]<sup>+</sup>: 218.3 [M + H]<sup>+</sup>, found 219.7.</p></sec><sec><label>4.2.2.2</label><title>Methyl 2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetate (3b)</title><p>Viscous liquid: yield 30.5 g, 84%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 7.39&#x02013;7.31 (s, 1H), 6.97&#x02013;6.58 (s, 1H), 3.72 (s, 1H), 3.68 (s, 3H), 2.45&#x02013;2.42 (s, 1H), 1.90&#x02013;1.86 (m, 1H), 1.66&#x02013;1.45 (m, 6H), 1.30&#x02013;1.23 (m, 1H). HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>14</sub>H<sub>15</sub>F<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 272.27 [M + H]<sup>+</sup>, found 272.27.</p></sec></sec><sec><label>4.2.3</label><title>Synthesis of substitutes 2-cyclopentyl-2-phenylacetohydrazide (4a &#x00026; 4b)</title><p>To a solution of substituted methyl 2-cyclopentyl-2-phenylacetate (3a or 3b) (20 g, 1.0 eq.) in 100 mL of ethanol was added 98% hydrazine hydride (18.3 g, 4.0 eq.) at 20&#x02013;30 &#x000b0;C and the reaction mixture was stirred at 80 &#x000b0;C for 24 h. After completion, the reaction mixture concentrated under reduced pressure, obtained solid washed with pentane to offered the substitutes 2-cyclopentyl-2-phenylacetohydrazides 4a and 4b, yield: 18 g, 90%.</p><sec><label>4.2.3.1</label><title>2-Cyclopentyl-2-phenylacetohydrazide (4a)</title><p>Viscous liquid: yield 22.3 g, 89%, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 9.18 (s, 1H), 7.34&#x02013;7.16 (m, 5H), 4.22 (b, 2H), 3.06&#x02013;3.02 (d, <italic toggle="yes">J</italic> = 11.1 Hz, 1H), 2.57&#x02013;2.54 (m, 1H), 1.72&#x02013;1.27 (m, 7H), 0.93&#x02013;0.86 (m, 1H). HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O]<sup>+</sup>: 218.3 [M + H]<sup>+</sup>, found 219.8.</p></sec><sec><label>4.2.3.2</label><title>2-Cyclopentyl-2-(2,4,5-trifluorophenyl)acetohydrazide (4b)</title><p>Viscous liquid: yield 22 g, 88%, <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 5.78 (s, 1H), 5.29 (s, 1H), 3.69 (s, 3H), 2.21 (t, <italic toggle="yes">J</italic> = 2.4 Hz, 6H). HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>13</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O]<sup>+</sup>: 272.27 [M + H]<sup>+</sup>, found 273.1.</p></sec></sec><sec><label>4.2.4</label><title>Synthesis of substituted <italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives (6a&#x02013;g &#x00026; 7a&#x02013;g)</title><p>A mixture of cinnamic acid derivative (1.0 eq.), HATU (1.5 eq.) and DIPEA (2.5 eq.) in DMF (10 vol.) was stirred at 20&#x02013;30 &#x000b0;C for 1 hour. Then substitutes 2-cyclopentyl-2-phenylacetohydrazide (4a/4b, 1 eq.) was added, and the resulting mixture was stirred at 20&#x02013;30 &#x000b0;C overnight. After completion of reaction, the reaction mixture poured into ice cold water, followed by ethyl acetate (10 vol.). The organic layer was separated, washed with 10% NaCl solution, dried over sodium sulphate and evaporated under vacuum to obtain crude product. These crude products were purified by column-chromatography (EtOAc/Hexane) to afford pure targeted compounds 6a&#x02013;g and 7a&#x02013;g.</p><sec><label>4.2.4.1</label><title>
<italic toggle="yes">N</italic>&#x02032;-(2-Cyclopentyl-2-phenylacetyl)cinnamohydrazide (6a)</title><p>Off-white solid, 113 mg, 71% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3200, 3058, 3025, 2945, 2862, 1640, 1590, 1494, 1462, 1329, 1184, 1157, 1072, 1030, 967, 855, 756, 735, 695, 656, 562, 531. <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.3&#x02013;10.14 (b, 1H), 7.58&#x02013;7.12 (m, 10H), 6.66&#x02013;6.61 (d, <italic toggle="yes">J</italic> = 15.9 Hz, 1H), 2.58&#x02013;2.2 (m, 1H), 1.98&#x02013;1.28 (m, 7H), 0.99&#x02013;0.92 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.26, 163.45, 140.06, 140.01, 134.57, 129.76, 128.98, 128.11, 127.64, 126.68, 119.40, 55.05, 42.41, 30.76, 30.23, 24.65, 24.46. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 348.45 [M + H]<sup>+</sup>, found 349.5.</p></sec><sec><label>4.2.4.2</label><title>3-(2-Bromophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)acrylohydrazide (6b)</title><p>Off-white solid, 137 mg, 70% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3201, 2947, 2859, 1639, 1589, 1472, 1324, 1268, 1200, 1183, 1023, 964, 853, 796, 755, 743, 723, 700, 658, 582, 543. <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.29&#x02013;10.25 (d, <italic toggle="yes">J</italic> = 9.9 Hz, 2H), 7.77&#x02013;7.67 (m, 3H), 7.47&#x02013;7.19 (m, 8H), 6.66&#x02013;6.61 (d, <italic toggle="yes">J</italic> = 15.6 Hz, 1H), 2.56&#x02013;2.55 (m, 1H), 1.81&#x02013;1.31 (m, 8H), 0.99&#x02013;0.92 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.27, 162.89, 140, 137.89, 134.09, 133.23, 131.42, 128.4, 128.12, 127.73, 126.7, 124.26, 122.57, 55.06, 42.38, 30.77, 30.23, 24.64, 24.45. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 427.34 [M + H]<sup>+</sup>, found 429.6.</p></sec><sec><label>4.2.4.3</label><title>3-(3-Bromophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)acrylohydrazide (6c)</title><p>Off-white solid, 156 mg, 80% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3180, 3030, 2948, 2858, 1661, 1640, 1588, 1464, 1368, 1270, 1200, 1180, 1071, 1032, 966, 854, 784, 719, 698, 663, 552. <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.29 (s, 1H), 10.16 (s, 1H), 7.78 (s, 1H), 7.6&#x02013;7.55 (dd, <italic toggle="yes">J</italic> = 8.1 Hz, 2H), 7.49&#x02013;7.09 (m, 7H), 6.7&#x02013;6.65 (d, <italic toggle="yes">J</italic> = 15.9 Hz, 1H), 2.56&#x02013;2.5 (m, 1H), 1.76&#x02013;1.3 (m, 8H), 0.96&#x02013;0.94 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.19, 168.93, 163.02, 156.08, 140.55, 140.03, 138.38, 137.14, 132.26, 131.06, 130.25, 128.4, 128.11, 128.03, 127.96, 126.68, 126.54, 126.42, 122.26, 121.08, 55.15, 55.02, 51.94, 42.50, 42.41, 30.75, 30.28, 30.23, 30.15, 24.87, 24.64, 24.45. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 427.34 [M + H]<sup>+</sup>, found 425.1.</p></sec><sec><label>4.2.4.4</label><title>3-(4-Bromophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)acrylohydrazide (6d)</title><p>Off-white solid, 147 mg, 75% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3192, 3025, 2946, 2864, 1637, 1591, 1488, 1461, 1322, 1202, 1181, 1073, 1011, 972, 859, 815, 743, 697, 645, 558, 527. <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.26&#x02013;10.16 (d, <italic toggle="yes">J</italic> = 29.7 Hz, 2H), 7.63&#x02013;7.05 (m, 10H), 6.67&#x02013;6.62 (d, <italic toggle="yes">J</italic> = 15.6 Hz, 1H), 2.58&#x02013;2.49 (m, 1H), 1.81&#x02013;1.30 (m, 8H), 1.01&#x02013;0.92 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.24, 163.23, 140.04, 138.75, 133.86, 131.94, 129.6, 128.11, 126.68, 122.95, 120.25, 55.03, 42.4, 30.75, 30.23, 24.65, 24.45. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 427.34 [M + H]<sup>+</sup>, found 429.6.</p></sec><sec><label>4.2.4.5</label><title>
<italic toggle="yes">N</italic>&#x02032;-(2-Cyclopentyl-2-phenylacetyl)-3-(<italic toggle="yes">p</italic>-tolyl)acrylohydrazide (6e)</title><p>Off-white solid, 118 mg, 71% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3193, 3024, 2945, 2864, 2819, 1693, 1635, 1590, 1512, 1456, 1386, 1203, 1180, 1144, 1110, 1034, 973, 861, 810, 771, 725, 697, 653, 561, 530.<sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.24 (b, 1H), 10.09 (b, 1H), 9.01 (m, 1H), 7.57&#x02013;7.21 (m, 9H), 6.6&#x02013;6.54 (d, <italic toggle="yes">J</italic> = 15.9 Hz, 1H), 3.32&#x02013;3.2 (m, 1H), 2.33 (s, 3H), 1.82&#x02013;1.31 (m, 8H), 0.98&#x02013;0.96 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.28, 163.64, 140.07, 139.97, 139.58, 131.83, 129.57, 128.1, 127.62, 126.66, 118.32, 55.05, 45.14, 44.78, 42.41, 30.76, 30.23, 24.64, 24.45, 20.95. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 362.47 [M + H]<sup>+</sup>, found 321.</p></sec><sec><label>4.2.4.6</label><title>3-(4-Fluoro)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)acrylohydrazide (6f)</title><p>Off-white solid, 139 mg, 83% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3196, 3026, 2951, 2864, 1639, 1589, 1507, 1457, 1327, 1229, 1199, 1179, 1157, 1096, 1032, 967, 871, 827, 779, 726, 696, 638, 530.<sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.26 (b, 1H), 10.13 (b, 1H), 7.66&#x02013;7.65 (m, 2H), 7.39&#x02013;7.41 (dd, 2H), 7.53&#x02013;7.50 (d, <italic toggle="yes">J</italic> = 15 Hz, 1H), 7.16&#x02013;7.32 (m, 5H), 6.61&#x02013;6.55 (d, <italic toggle="yes">J</italic> = 15.9 Hz, 1H), 3.31&#x02013;3.33 (d, <italic toggle="yes">J</italic> = 10 Hz, 1H), 2.5&#x02013;2.51 (m, 1H), 1.33&#x02013;1.82 (m, 7H), 0.95&#x02013;0.99 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.73, 162.31&#x02013;164.3, 163.89, 140.54, 139.29, 131.71, 130.36, 128.6, 128.57, 127.14, 116.51, 119.78, 55.53, 42.89, 31.24, 30.71, 25.12, 24.93. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>23</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 366.44 [M + H]<sup>+</sup>, found 367.2.</p></sec><sec><label>4.2.4.7</label><title>3-(3-Nitrophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-phenylacetyl)acrylohydrazide (6g)</title><p>Pale yellow solid, 140 mg, 78% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3167, 3028, 2952, 2866, 1642, 1590, 1530, 1468, 1346, 1267, 1206, 1184, 1074, 1031, 973, 902, 861, 834, 805, 751, 732, 712, 654, 562, 545, 517. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.33 (S, 1H), 10.24 (s, 1H), 8.4 (s, 1H), 8.23&#x02013;8.21 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H), 8.04&#x02013;8.02 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 1H), 7.73&#x02013;7.72 (t, <italic toggle="yes">J</italic> = 8 Hz, 1H), 7.65&#x02013;7.62 (d, <italic toggle="yes">J</italic> = 16 Hz, 1H), 7.38&#x02013;7.21 (m, 5H), 6.84&#x02013;6.81 (d, <italic toggle="yes">J</italic> = 15.5 Hz, 1H), 2.57&#x02013;2.53 (m, 1H), 1.80&#x02013;1.3 (m, 8H), 0.99&#x02013;0.94 (m, 1H). <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 171.16, 162.77, 148.3, 140.02, 137.73, 136.45, 133.82, 130.52, 128.12, 126.7, 124.01, 122.32, 121.91, 55.02, 42.43, 30.76, 30.23, 24.64, 24.45. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>]<sup>+</sup>: 393.44 [M + H]<sup>+</sup>, found 394.4.</p></sec><sec><label>4.2.4.8</label><title>
<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)cinnamohydrazide (7a)</title><p>Off-white solid, 96 mg, 65% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3184, 2953, 2869, 1682, 1642, 1610, 1513, 1423, 1335, 1257, 1207, 1185, 1148, 976, 878, 857, 761, 708, 615, 518. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.36 (s, 1H), 10.13 (s, 1H), 7.67&#x02013;7.62 (m, 1H), 7.59&#x02013;7.49 (m, 4H), 7.44&#x02013;7.40 (m, 3H), 6.65&#x02013;6.62 (d, <italic toggle="yes">J</italic> = 15.5 Hz, 1H), 3.68&#x02013;3.66 (d, <italic toggle="yes">J</italic> = 11 Hz, 1H), 2.44&#x02013;2.42 (d, <italic toggle="yes">J</italic> = 10.5 Hz, 1H), 1.83&#x02013;1.79 (m, 1H), 1.67&#x02013;1.65 (m 1H), 1.58&#x02013;1.49 (m, 6H), 0.99&#x02013;0.91 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): &#x02212;118.79, &#x02212;136.45, &#x02212;142.94. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 170.04, 163.68, 140.26, 134.51, 129.82, 128.99, 127.68, 119.25, 117.15, 105.7, 45.47, 43, 30.52, 29.99, 24.48, 24.27. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 402.2 [M + H]<sup>+</sup>, found 403.1.</p></sec><sec><label>4.2.4.9</label><title>
<italic toggle="yes">N</italic>&#x02032;-(2-Cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)-3-(<italic toggle="yes">p</italic>-tolyl)acrylohydrazide (7b)</title><p>Off-white solid, 104 mg, 68% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3186, 3029, 2948, 2867, 1666, 1632, 1587, 1513, 1461, 1424, 1330, 1255, 1197, 1184, 1156, 973, 884, 862, 807, 758, 709, 646, 524, 514. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.34 (s, 1H), 10.07 (s, 1H), 7.67&#x02013;7.61 (m, 1H), 7.55&#x02013;7.45 (m, 4H), 7.24&#x02013;7.22 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 6.58&#x02013;6.55 (dd, <italic toggle="yes">J</italic> = 15.5 Hz, 1H), 3.67&#x02013;3.65 (d, <italic toggle="yes">J</italic> = 2 Hz, 11H), 2.44&#x02013;2.42 (m, 1H), 2.32 (s, 3H), 1.81&#x02013;1.78 (m, 1H), 1.67&#x02013;1.65 (m, 1H), 1.58&#x02013;1.49 (m, 6H), 0.99&#x02013;0.91 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.79, 136.46, 142.95.<sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 170.04, 163.5, 156.04, 140.2, 139.56, 131.78, 129.56, 127.65, 123.72, 118.16, 114.75, 105.67, 45.45, 43.02, 30.52, 24.47, 22.2. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>23</sub>H<sub>23</sub> F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 416.44 [M + H]<sup>+</sup>, found 417.2.</p></sec><sec><label>4.2.4.10</label><title>3-(4-Bromophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)acrylohydrazide (7c)</title><p>Off-white solid, 131 mg, 74% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3176, 3030, 2945, 2866, 1633, 1587, 1514, 1488, 1463, 1424, 1330, 1256, 1200, 1157, 1074, 1012, 971, 884, 863, 814, 771, 709, 695, 646, 518. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.38 (s, 1H), 10.16 (s, 1H), 7.63&#x02013;7.61 (m, 3H), 7.54&#x02013;7.53 (m, 4H), 6.66&#x02013;6.63 (d, <italic toggle="yes">J</italic> = 16 Hz, 1H), 3.68&#x02013;3.65 (d, <italic toggle="yes">J</italic> = 10.5 Hz, 1H), 2.49&#x02013;2.1 (m, 1H), 1.9&#x02013;1.78 (m, 1H), 1.68&#x02013;1.64 (m, 1H), 1.58&#x02013;1.45 (m, 6H), 0.99&#x02013;0.91 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.78, 136.42, 142.93. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 170.02, 163.46, 139.01, 133.81, 131.94, 129.64, 123.02, 120.09, 117.11, 105.46, 45.47, 43, 30.52, 29.98, 24.48, 24.27. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>20</sub>Br F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 481.31 [M + H]<sup>+</sup>, found 478.9.</p></sec><sec><label>4.2.4.11</label><title>3-(3-Chlorophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)acrylohydrazide (7d)</title><p>Off-white solid, 128 mg, 80% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3186, 2951, 2869, 1685, 1590, 1514, 1475, 1423, 1331, 1256, 1203, 1150, 1078, 971, 879, 851, 784, 703, 683, 640, 523. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.39 (s, 1H), 10.15 (s, 1H), 7.67&#x02013;7.61 (m, 2H), 7.56&#x02013;7.45 (m, 5H), 6.7&#x02013;6.67 (d, <italic toggle="yes">J</italic> = 16 Hz, 1H), 3.68&#x02013;3.66 (d, <italic toggle="yes">J</italic> = 11 Hz, 1H), 2.49&#x02013;2.41 (m, 1H), 1.82&#x02013;1.78 (m, 1H), 1.68&#x02013;1.64 (m, 1H), 1.58&#x02013;1.49 (s, 6H), 0.99&#x02013;0.96 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.79, 136.42, 142.92. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 169.99, 163.31, 138.72, 136.83, 133.7, 130.81, 129.43, 127.44, 126.11, 120.95, 105.3, 45.46, 42.99, 30.52, 29.99, 24.48, 24.27. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>20</sub>Cl F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 436.86 [M + H]<sup>+</sup>, found 437.1.</p></sec><sec><label>4.2.4.12</label><title>
<italic toggle="yes">N</italic>&#x02032;-(2-Cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)-3-(4-methoxyphenyl)acrylohydrazide (7e)</title><p>Off-white solid, 141 mg, 89% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3201, 3025, 2954, 2868, 2838, 1667, 1630, 1583, 1512, 1458, 1423, 1331, 1306, 1287, 1259, 1196, 1174, 1157, 1110, 1030, 973, 884, 864, 830, 809, 783, 757, 698, 645, 550, 525. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.31 (s, 1H), 10.01 (s, 1H), 7.67&#x02013;7.61 (m, 1H), 7.54&#x02013;7.43 (m, 4H), 6.99&#x02013;6.97 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 1H), 6.49&#x02013;6.46 (d, <italic toggle="yes">J</italic> = 16 Hz, 1H), 3.8 (s, 3H), 3.67&#x02013;3.63 (d, <italic toggle="yes">J</italic> = 11 Hz, 1H), 2.49&#x02013;2.44 (m, 1H), 1.83&#x02013;1.77 (m, 1H), 1.69&#x02013;1.64 (m, 1H), 1.59&#x02013;1.4 (m, 6H), 0.99&#x02013;0.95 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.8, 136.48, 142.96. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 170.06, 164.05, 160.6, 139.97, 129.32, 127.09, 116.66, 114.43, 55.28, 45.46, 43.01, 30.52, 29.98, 24.48, 24.27. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>23</sub>H<sub>23</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup>: 432.44 [M + H]<sup>&#x02212;</sup>, found 433.1.</p></sec><sec><label>4.2.4.13</label><title>3-(3-Bromophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)acrylohydrazide (7f)</title><p>Off-white solid, 152 mg, 86% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3747, 3178, 3034, 2962, 2869, 1646, 1598, 1513, 1472, 1424, 1335, 1258, 1204, 1157, 1072, 970, 890, 860, 844, 809, 781, 741, 719, 697, 663, 642, 603, 522. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.39 (s, 1H), 10.14 (s, 1H), 7.79&#x02013;7.67 (t, <italic toggle="yes">J</italic> = 1.5 Hz, 1H), 7.65&#x02013;7.57 (m, 3H), 7.53&#x02013;7.4 (m, 2H), 7.38&#x02013;7.32 (t, <italic toggle="yes">J</italic> = 8 Hz, 1H), 6.69&#x02013;6.66 (m, <italic toggle="yes">J</italic> = 16 Hz, 1H), 3.68&#x02013;3.66 (d, <italic toggle="yes">J</italic> = 11 Hz, 1H), 2.49&#x02013;2.44 (m, 1H), 1.81&#x02013;1.78 (m, 1H), 1.67&#x02013;1.66 (m, 1H), 1.58&#x02013;1.44 (m, 6H), 0.99&#x02013;0.96 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.79, 136.42, 142.92. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 169.98, 163.28, 138.64, 137.09, 132.33, 131.07, 130.3, 126.47, 122.27, 120.93, 105.54, 45.46, 42.99, 30.52, 29.99, 24.48, 24.27. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>20</sub>BrF<sub>3</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup>: 481.31 [M + H]<sup>+</sup>, found 481.2.</p></sec><sec><label>4.2.4.14</label><title>3-(3-Nitrophenyl)-<italic toggle="yes">N</italic>&#x02032;-(2-cyclopentyl-2-(2,4,5-trifluorophenyl)acetyl)acrylohydrazide (7g)</title><p>Brown colored solid, 145 mg, 89% yield, IR (KBr, cm<sup>&#x02212;1</sup>): 3198, 3073, 2948, 2865, 1641, 1586, 1530, 1462, 1426, 1354, 1253, 1205, 1157, 1099, 961, 886, 856, 808, 775, 751, 718, 700, 660, 634, 603, 523. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 10.43 (s, 1H), 10.22 (s, 1H), 8.41 (d, <italic toggle="yes">J</italic> = 2 Hz, 1H), 8.23&#x02013;8.22 (dd, <italic toggle="yes">J</italic> = 1.5, 1 Hz, 1H), 8.21 (d, <italic toggle="yes">J</italic> = 0.5 Hz, 1H), 7.73&#x02013;7.7 (t, <italic toggle="yes">J</italic> = 8 Hz, 1H), 7.66&#x02013;7.63 (m, 2H), 7.53&#x02013;7.5 (m, 1H), 6.84&#x02013;6.81 (d, <italic toggle="yes">J</italic> = 16 Hz, 1H), 3.69&#x02013;3.67 (d, <italic toggle="yes">J</italic> = 11 Hz, 1H), 2.49&#x02013;2.43 (m, 1H), 1.86&#x02013;1.8 (m, 1H), 1.67&#x02013;1.65 (m, 1H), 1.58&#x02013;1.4 (m, 6H), 0.99&#x02013;0.96 (m, 1H). <sup>19</sup>F NMR (500 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>): <italic toggle="yes">&#x003b4;</italic> (ppm): 118.79, 136.41, 142.92. <sup>13</sup>C NMR spectrum, <italic toggle="yes">&#x003b4;</italic><sub>c</sub>, ppm, DMSO-<italic toggle="yes">d</italic><sub>6</sub>: 169.93, 163.01, 148.29, 146.93, 137.96, 136.4, 133.83, 130.5, 123.79, 122.18, 121.95, 117.25, 105.69, 45.73, 43.11, 30.51, 24.88. HRMS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. For [C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>]<sup>+</sup>: 447.41 [M + H]<sup>+</sup>, found 445.9.</p></sec></sec></sec><sec><label>4.3.</label><title>&#x003b1;-Glucosidase inhibitory assay</title><p>The test compounds were evaluated for their &#x003b1;-glucosidase inhibitory activity following the methodology outlined by Pistia <italic toggle="yes">et al.</italic><sup><xref rid="cit62" ref-type="bibr">62</xref></sup> and Bhatia <italic toggle="yes">et al.</italic><sup><xref rid="cit63" ref-type="bibr">63</xref></sup> The test compounds and Acarbose were both dissolved in phosphate buffer at a pH of 6.8. The compounds at varied concentrations ranging from 50 to 200 &#x003bc;g mL<sup>&#x02212;1</sup> were combined with 50 &#x003bc;L of &#x003b1;-glucosidase (maltase) enzyme solution (1 U mL<sup>&#x02212;1</sup>) from Yeast (Sisco Research Laboratories Pvt. Ltd). The mixer was placed at a temperature of 37 &#x000b0;C for duration of 15 minutes, after the addition of 0.1 M phosphate buffer (pH 6.8). Afterward, 25 &#x003bc;l of substrate buffer was introduced into the system to initiate the reaction, and the incubation was prolonged at a temperature of 37 &#x000b0;C for a length of 15 minutes. Finally, the reaction was stopped by adding 50 &#x003bc;l of a 0.2 M sodium carbonate solution, thereby terminating the processes. The measurement was determined at a wavelength of 450 nm. Acarbose was used as a standard chemical and given at various doses ranging from 50 to 200 &#x003bc;g mL<sup>&#x02212;1</sup>. The measurement of enzyme activity was carried out as follows.</p><p>The formula for calculating the percentage is (OD<sub>blank</sub> &#x02212; OD<sub>sample</sub>) divided by OD<sub>blank</sub>, multiplied by 100.</p><p>A unit of enzyme may be accurately defined as the amount of &#x003b1;-glucosidase enzyme required to generate one micromole of <italic toggle="yes">p</italic>-nitrophenol (product) from <italic toggle="yes">p</italic>-nitrophenyl-&#x003b1;-<sc>d</sc>-glucopyranoside (substrate) for a time of one minute. The IC<sub>50</sub>, representing the concentration required to inhibit 50% of the enzyme activity, was determined by fitting a regression equation to a graph that plotted concentration (varying from 50&#x02013;200 &#x003bc;g mL<sup>&#x02212;1</sup>) on the <italic toggle="yes">X</italic>-axis and percentage of inhibition on the <italic toggle="yes">Y</italic>-axis for various fractions and extracts.</p></sec><sec><label>4.4.</label><title>Molecular docking</title><p>To ascertain the most effective way of binding a ligand to a target protein, molecular docking is utilized. When the ligand forms a stable combination with other potential ligands, this is very beneficial. A highly effective technique for examining the molecular interactions between ligands and proteins is docking.</p><sec><label>4.4.1</label><title>UCSF chimera</title><p>Structural biologists, medicinal researchers, and experts in the fields of bioinformatics and drug development regularly use the UCSF chimera programme to further enhance their understanding of molecular structure and function. A flexible software suite called chimera makes it possible to interactively explore and visualize molecular structures. It can help users comprehend pertinent data better, including conformational ensembles, supra-molecular assemblies, trajectories, density maps, and sequence alignments.</p></sec><sec><label>4.4.2</label><title>AutoDock Vina</title><p>The automated character of the AutoDock Vina molecular docking software is evident. The three-dimensional structure of the target protein exhibits enhanced binding of the ligand. Computational docking approaches, such as protein-ligand docking, blind docking, and site-specific docking, are performed using the reputable bioinformatics software AutoDock Vina. Along with docking, AutoDock Vina, sometimes called AutoDock tools, helps modify the structure of ligands and proteins. This method makes it possible to evaluate molecular assemblies of different sizes. Alpha-glucosidase's crystal structure (PDB ID:<uri>3WY1</uri>) was obtained from the RCSB PDB database. The data supplied includes the number of hydrogen bonds (H-bonds) at position 44, binding energy, and root mean square deviation (RMSD). The protein target's docking location was determined to be a grid box with dimensions of 21 &#x000d7; 21 &#x000d7; 21 and parameters of <italic toggle="yes">X</italic>: &#x02212;9.1, <italic toggle="yes">Y</italic>: &#x02212;7.4, <italic toggle="yes">Z</italic>: 24.2 &#x000c5;. Inside this grid box, significant chemical substances for interaction were found.<sup><xref rid="cit25" ref-type="bibr">25</xref></sup></p></sec></sec><sec><label>4.5.</label><title>Swiss ADME</title><sec><label>4.5.1</label><title>Evaluation of physico-chemical properties</title><p>SMILES representations for every planned chemical have been created, and the process has been completed with success.<sup><xref rid="cit64" ref-type="bibr">64</xref></sup> SwissADME is an online tool that may be accessed at <uri xlink:href="http://www.swissadme.ch/index.php">http://www.swissadme.ch/index.php</uri>. The compounds SMILES representations and corresponding chemical codes were entered into the tool. The programme has a &#x0201c;run&#x0201d; button function that helps with parameter calculating once the submission process is completed. An examination of the data was then performed on the collected results, which were available in both PDF and CSV formats.</p></sec></sec></sec><sec sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in this published article and its ESI files.<xref rid="fn1" ref-type="fn">&#x02020;</xref></p></sec><sec><title>Ethics approval</title><p>This article does not contain any studies with animals performed by any of the authors.</p></sec><sec><title>Consent for publication</title><p>We authorize to publish the article without any conflict.</p></sec><sec><title>Author contributions</title><p>Ram Reddy Mudireddy: investigation, formal analysis, methodology, and writing &#x02013; original draft. Rambabu Gundla: project administration and supervision. Baji Baba Shaik: investigation, and software. Anoop Bodapati: validation, and resources. Panasa Mahesh: conceptualisation, and writing &#x02013; original draft. Shiva Sravan Naidu: data curation, and funding acquisition. Damodar Tirumalasetti: formal analysis, and writing &#x02013; review &#x00026; editing. Naresh Kumar Katari: visualization and writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>The authors declare no conflict of interest regarding the publication of this manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="RA-015-D5RA01971K-s001" position="float" content-type="local-data"><label>RA-015-D5RA01971K-s001</label><media xlink:href="RA-015-D5RA01971K-s001.pdf" id="d67e2580" position="anchor"/></supplementary-material></sec></body><back><ack><p>Dr Rambabu Gundla acknowledges DBT-BIRAC (BT/AIR01566/PACE-27/22) for financial assistance and GITAM for the facility.</p></ack><ref-list><title>References</title><ref id="cit1"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dale Abel</surname><given-names>E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gloyn</surname><given-names>A. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Evans-Molina</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Joseph</surname><given-names>J. J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Misra</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pajvani</surname><given-names>U. B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Simcox</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Susztak</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Drucker</surname><given-names>D. J.</given-names></name>
</person-group><article-title>Diabetes mellitus&#x02014;Progress and opportunities in the evolving epidemic</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>3789</fpage><lpage>3820</lpage><ext-link xlink:href="10.1016/j.cell.2024.06.029" ext-link-type="doi">https://dx.doi.org/10.1016/j.cell.2024.06.029</ext-link><pub-id pub-id-type="doi">10.1016/j.cell.2024.06.029</pub-id><pub-id pub-id-type="pmid">39059357</pub-id>
</element-citation></ref><ref id="cit2"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>N. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sattar</surname><given-names>N.</given-names></name>
</person-group><article-title>Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>685</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00877-z</pub-id><pub-id pub-id-type="pmid">37193856</pub-id>
</element-citation></ref><ref id="cit3"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babu</surname><given-names>S.</given-names></name>
</person-group><article-title>An update on diagnosis and therapeutics for type-2 diabetes mellitus</article-title><source>Bioinformation</source><year>2023</year><volume>19</volume><fpage>295</fpage><lpage>298</lpage><ext-link xlink:href="10.6026/97320630019295" ext-link-type="doi">https://dx.doi.org/10.6026/97320630019295</ext-link><pub-id pub-id-type="doi">10.6026/97320630019295</pub-id><pub-id pub-id-type="pmid">37808382</pub-id>
</element-citation></ref><ref id="cit4"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moran</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Beare</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Phan</surname><given-names>T. G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bruce</surname><given-names>D. G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Callisaya</surname><given-names>M. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Srikanth</surname><given-names>V.</given-names></name>
</person-group><article-title>Type 2 diabetes mellitus and biomarkers of neurodegeneration</article-title><source>Neurology</source><year>2015</year><volume>85</volume><fpage>1123</fpage><lpage>1130</lpage><ext-link xlink:href="10.1212/wnl.0000000000001982" ext-link-type="doi">https://dx.doi.org/10.1212/wnl.0000000000001982</ext-link><pub-id pub-id-type="doi">10.1212/WNL.0000000000001982</pub-id><pub-id pub-id-type="pmid">26333802</pub-id>
</element-citation></ref><ref id="cit5"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mills</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Acquah</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Klenk</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Glassen</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pirson</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Albert</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hoang</surname><given-names>D. T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Van</surname><given-names>T. N.</given-names></name>
</person-group><article-title>Type 2 Diabetes Mellitus (T2DM) and Carbohydrate Metabolism in Relation to T2DM from Endocrinology, Neurophysiology, Molecular Biology, and Biochemistry Perspectives</article-title><source>J. Evidence-Based Complementary Altern. Med.</source><year>2022</year><volume>2022</volume><fpage>e1708769</fpage><pub-id pub-id-type="doi">10.1155/2022/1708769</pub-id></element-citation></ref><ref id="cit6"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bogatyrev</surname><given-names>S. N.</given-names></name>
</person-group><article-title>Physical activity and type 2 diabetes mellitus risk: population studies review</article-title><source>Diabetes Mellitus</source><year>2017</year><volume>19</volume><fpage>486</fpage><pub-id pub-id-type="doi">10.14341/dm8030</pub-id></element-citation></ref><ref id="cit7"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonge</surname><given-names>K. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>D'Alessio</surname><given-names>D. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>M. W.</given-names></name>
</person-group><article-title>Brain control of blood glucose levels: implications for the pathogenesis of type 2 diabetes</article-title><source>Diabetologia</source><year>2020</year><volume>64</volume><fpage>5</fpage><lpage>14</lpage><ext-link xlink:href="10.1007/s00125-020-05293-3" ext-link-type="doi">https://dx.doi.org/10.1007/s00125-020-05293-3</ext-link><pub-id pub-id-type="doi">10.1007/s00125-020-05293-3</pub-id><pub-id pub-id-type="pmid">33043401</pub-id>
</element-citation></ref><ref id="cit8"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maida</surname><given-names>C. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Daidone</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pacinella</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Norrito</surname><given-names>R. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tuttolomondo</surname><given-names>A.</given-names></name>
</person-group><article-title>Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>2397</fpage><ext-link xlink:href="10.3390/ijms23042397" ext-link-type="doi">https://dx.doi.org/10.3390/ijms23042397</ext-link><pub-id pub-id-type="doi">10.3390/ijms23042397</pub-id><pub-id pub-id-type="pmid">35216512</pub-id>
</element-citation></ref><ref id="cit9"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menon</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Syed</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kumar Yadav</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Menon</surname><given-names>M.</given-names></name>
</person-group><article-title>Diabetes and Stroke&#x02014;A Focused Review</article-title><source>J. Diabetol.</source><year>2024</year><volume>15</volume><fpage>247</fpage><lpage>257</lpage><ext-link xlink:href="10.4103/jod.jod_46_24" ext-link-type="doi">https://dx.doi.org/10.4103/jod.jod_46_24</ext-link><pub-id pub-id-type="doi">10.4103/jod.jod_46_24</pub-id></element-citation></ref><ref id="cit10"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sagandira</surname><given-names>C. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Khasipo</surname><given-names>A. Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sagandira</surname><given-names>M. B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Watts</surname><given-names>P.</given-names></name>
</person-group><article-title>An overview of the synthetic routes to essential oral anti-diabetes drugs</article-title><source>Tetrahedron</source><year>2021</year><volume>96</volume><fpage>132378</fpage><ext-link xlink:href="10.1016/j.tet.2021.132378" ext-link-type="doi">https://dx.doi.org/10.1016/j.tet.2021.132378</ext-link><pub-id pub-id-type="doi">10.1016/j.tet.2021.132378</pub-id></element-citation></ref><ref id="cit11"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Dokmak</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bader</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Karaman</surname><given-names>R.</given-names></name>
</person-group><article-title>A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications</article-title><source>Life</source><year>2023</year><volume>13</volume><fpage>1012</fpage><ext-link xlink:href="10.3390/life13041012" ext-link-type="doi">https://dx.doi.org/10.3390/life13041012</ext-link><pub-id pub-id-type="doi">10.3390/life13041012</pub-id><pub-id pub-id-type="pmid">37109541</pub-id>
</element-citation></ref><ref id="cit12"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahl&#x000e9;n</surname><given-names>A. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Dashi</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Maslov</surname><given-names>I.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Attwood</surname><given-names>M. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Jonsson</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Trukhan</surname><given-names>V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Schi&#x000f6;th</surname><given-names>H. B.</given-names></name>
</person-group><article-title>Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales</article-title><source>Front. Pharmacol</source><year>2022</year><volume>12</volume><fpage>807548</fpage><ext-link xlink:href="10.3389/fphar.2021.807548" ext-link-type="doi">https://dx.doi.org/10.3389/fphar.2021.807548</ext-link><pub-id pub-id-type="doi">10.3389/fphar.2021.807548</pub-id><pub-id pub-id-type="pmid">35126141</pub-id>
</element-citation></ref><ref id="cit13"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lazzaroni</surname><given-names>E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ben Nasr</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Loretelli</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pastore</surname><given-names>I.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Plebani</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lunati</surname><given-names>M. E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Vallone</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bolla</surname><given-names>A. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Montefusco</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ippolito</surname><given-names>E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Berra</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>D'Addio</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zuccotti</surname><given-names>G. V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Fiorina</surname><given-names>P.</given-names></name>
</person-group><article-title>Anti-diabetic drugs and weight loss in patients with type 2 diabetes</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>171</volume><fpage>105782</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105782</pub-id><pub-id pub-id-type="pmid">34302978</pub-id>
</element-citation></ref><ref id="cit14"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.-C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>B.</given-names></name>
</person-group><article-title>Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis</article-title><source>Front. Endocrinol.</source><year>2021</year><volume>12</volume><fpage>735824</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.735824</pub-id></element-citation></ref><ref id="cit15"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mushtaq</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Azam</surname><given-names>U.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mehreen</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Naseer</surname><given-names>M. M.</given-names></name>
</person-group><article-title>Synthetic &#x003b1;-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>249</volume><fpage>115119</fpage><ext-link xlink:href="10.1016/j.ejmech.2023.115119" ext-link-type="doi">https://dx.doi.org/10.1016/j.ejmech.2023.115119</ext-link><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115119</pub-id><pub-id pub-id-type="pmid">36680985</pub-id>
</element-citation></ref><ref id="cit16"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dirir</surname><given-names>A. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Daou</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yousef</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yousef</surname><given-names>L. F.</given-names></name>
</person-group><article-title>A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes</article-title><source>Phytochem. Rev.</source><year>2021</year><volume>21</volume><fpage>1049</fpage><lpage>1079</lpage><ext-link xlink:href="10.1007/s11101-021-09773-1" ext-link-type="doi">https://dx.doi.org/10.1007/s11101-021-09773-1</ext-link><pub-id pub-id-type="doi">10.1007/s11101-021-09773-1</pub-id><pub-id pub-id-type="pmid">34421444</pub-id>
</element-citation></ref><ref id="cit17"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chadha</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>M.</given-names></name>
</person-group><article-title>Recent developments in synthetic &#x003b1;-glucosidase inhibitors: A comprehensive review with structural and molecular insight</article-title><source>J. Mol. Struct.</source><year>2023</year><volume>1281</volume><fpage>135115</fpage><ext-link xlink:href="10.1016/j.molstruc.2023.135115" ext-link-type="doi">https://dx.doi.org/10.1016/j.molstruc.2023.135115</ext-link><pub-id pub-id-type="doi">10.1016/j.molstruc.2023.135115</pub-id></element-citation></ref><ref id="cit18"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>A. P. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yoo</surname><given-names>S. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bao</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yeoh</surname><given-names>E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>S. P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mohan</surname><given-names>V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>McGill</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Twigg</surname><given-names>S. M.</given-names></name>
</person-group><article-title>Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management</article-title><source>Diabetes Res. Clin. Pract.</source><year>2023</year><volume>201</volume><fpage>110718</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2023.110718</pub-id><pub-id pub-id-type="pmid">37196707</pub-id>
</element-citation></ref><ref id="cit19"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>C. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gardner</surname><given-names>J. G.</given-names></name>
</person-group><article-title>Bacterial &#x003b1;-diglucoside metabolism: perspectives and potential for biotechnology and biomedicine</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2021</year><volume>105</volume><fpage>4033</fpage><lpage>4052</lpage><ext-link xlink:href="10.1007/s00253-021-11322-x" ext-link-type="doi">https://dx.doi.org/10.1007/s00253-021-11322-x</ext-link><pub-id pub-id-type="doi">10.1007/s00253-021-11322-x</pub-id><pub-id pub-id-type="pmid">33961116</pub-id>
</element-citation></ref><ref id="cit20"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Q.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>F.</given-names></name>
</person-group><article-title>Alpha-Glucosidase Inhibitory Peptides: Sources, Preparations, Identifications, and Action Mechanisms</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><fpage>4267</fpage><ext-link xlink:href="10.3390/nu15194267" ext-link-type="doi">https://dx.doi.org/10.3390/nu15194267</ext-link><pub-id pub-id-type="doi">10.3390/nu15194267</pub-id><pub-id pub-id-type="pmid">37836551</pub-id>
</element-citation></ref><ref id="cit21"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00106;orkovi&#x00107;</surname><given-names>I.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ga&#x00161;o-Soka&#x0010d;</surname><given-names>D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pichler</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>&#x00160;imunovi&#x00107;</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kopjar</surname><given-names>M.</given-names></name>
</person-group><article-title>Dietary Polyphenols as Natural Inhibitors of &#x003b1;-Amylase and &#x003b1;-Glucosidase</article-title><source>Life</source><year>2022</year><volume>12</volume><fpage>1692</fpage><ext-link xlink:href="10.3390/life12111692" ext-link-type="doi">https://dx.doi.org/10.3390/life12111692</ext-link><pub-id pub-id-type="doi">10.3390/life12111692</pub-id><pub-id pub-id-type="pmid">36362847</pub-id>
</element-citation></ref><ref id="cit22"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebovitz</surname><given-names>H. E.</given-names></name>
</person-group><article-title>Oral Antidiabetic Agents</article-title><source>Drugs</source><year>1992</year><volume>44</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2165/00003495-199200443-00004</pub-id><pub-id pub-id-type="pmid">1280574</pub-id>
</element-citation></ref><ref id="cit23"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>E. A. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Siddiqui</surname><given-names>M. J. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ang</surname><given-names>L. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sadikun</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>S. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>S. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Asmawi</surname><given-names>M. Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yam</surname><given-names>M. F.</given-names></name>
</person-group><article-title>Potent &#x003b1;-glucosidase and &#x003b1;-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin from Orthosiphon stamineus Benth as anti-diabetic mechanism</article-title><source>BMC Compl. Alternative Med.</source><year>2012</year><volume>12</volume><fpage>176</fpage><ext-link xlink:href="10.1186/1472-6882-12-176" ext-link-type="doi">https://dx.doi.org/10.1186/1472-6882-12-176</ext-link><pub-id pub-id-type="doi">10.1186/1472-6882-12-176</pub-id><pub-id pub-id-type="pmid">23039079</pub-id>
</element-citation></ref><ref id="cit24"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dabhi</surname><given-names>A. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>N. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>M. J.</given-names></name>
</person-group><article-title>Voglibose: An Alpha Glucosidase Inhibitor</article-title><source>J. Clin. Diagn. Res.</source><year>2013</year><volume>12</volume><fpage>3023</fpage><lpage>3027</lpage><pub-id pub-id-type="doi">10.7860/jcdr/2013/6373.3838</pub-id></element-citation></ref><ref id="cit25"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghani</surname><given-names>U.</given-names></name>
</person-group><article-title>Re-exploring promising &#x003b1;-glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding needle in the haystack</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>103</volume><fpage>133</fpage><lpage>162</lpage><ext-link xlink:href="10.1016/j.ejmech.2015.08.043" ext-link-type="doi">https://dx.doi.org/10.1016/j.ejmech.2015.08.043</ext-link><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.08.043</pub-id><pub-id pub-id-type="pmid">26344912</pub-id>
</element-citation></ref><ref id="cit26"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghani</surname><given-names>U.</given-names></name>
</person-group><article-title>Re-exploring promising &#x003b1;-glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding needle in the haystack</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>103</volume><fpage>133</fpage><lpage>162</lpage><ext-link xlink:href="10.1016/j.ejmech.2015.08.043" ext-link-type="doi">https://dx.doi.org/10.1016/j.ejmech.2015.08.043</ext-link><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.08.043</pub-id><pub-id pub-id-type="pmid">26344912</pub-id>
</element-citation></ref><ref id="cit27"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aoki</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Muraoka</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Togashi</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Terauchi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Comparison of Adverse Gastrointestinal Effects of Acarbose and Miglitol in Healthy Men: A Crossover Study</article-title><source>Intern. Med.</source><year>2010</year><volume>49</volume><fpage>1085</fpage><lpage>1087</lpage><ext-link xlink:href="10.2169/internalmedicine.49.3218" ext-link-type="doi">https://dx.doi.org/10.2169/internalmedicine.49.3218</ext-link><pub-id pub-id-type="doi">10.2169/internalmedicine.49.3218</pub-id><pub-id pub-id-type="pmid">20558922</pub-id>
</element-citation></ref><ref id="cit28"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurebayashi</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Watada</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kawasumi</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kawamori</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hirose</surname><given-names>T.</given-names></name>
</person-group><article-title>Efficacy and Adverse Effects of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study</article-title><source>Endocr. J.</source><year>2006</year><volume>53</volume><fpage>213</fpage><lpage>217</lpage><ext-link xlink:href="10.1507/endocrj.53.213" ext-link-type="doi">https://dx.doi.org/10.1507/endocrj.53.213</ext-link><pub-id pub-id-type="doi">10.1507/endocrj.53.213</pub-id><pub-id pub-id-type="pmid">16618980</pub-id>
</element-citation></ref><ref id="cit29"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sels</surname><given-names>J.-P. J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Huijberts</surname><given-names>M. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wolffenbuttel</surname><given-names>B. H.</given-names></name>
</person-group><article-title>Miglitol, a new &#x003b1;-glucosidase inhibitor</article-title><source>Expert Opin. Pharmacother.</source><year>1999</year><volume>1</volume><fpage>149</fpage><lpage>156</lpage><ext-link xlink:href="10.1517/14656566.1.1.149" ext-link-type="doi">https://dx.doi.org/10.1517/14656566.1.1.149</ext-link><pub-id pub-id-type="doi">10.1517/14656566.1.1.149</pub-id><pub-id pub-id-type="pmid">11249557</pub-id>
</element-citation></ref><ref id="cit30"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Min</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.-H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity</article-title><source>J. Med. Chem.</source><year>2024</year><volume>67</volume><fpage>8406</fpage><lpage>8419</lpage><ext-link xlink:href="10.1021/acs.jmedchem.4c00676" ext-link-type="doi">https://dx.doi.org/10.1021/acs.jmedchem.4c00676</ext-link><pub-id pub-id-type="doi">10.1021/acs.jmedchem.4c00676</pub-id><pub-id pub-id-type="pmid">38723203</pub-id>
</element-citation></ref><ref id="cit31"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.-H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Novel thiosemicarbazide-based &#x003b2;-carboline derivatives as &#x003b1;-glucosidase inhibitors: Synthesis and biological evaluation</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>275</volume><fpage>116595</fpage><ext-link xlink:href="10.1016/j.ejmech.2024.116595" ext-link-type="doi">https://dx.doi.org/10.1016/j.ejmech.2024.116595</ext-link><pub-id pub-id-type="doi">10.1016/j.ejmech.2024.116595</pub-id><pub-id pub-id-type="pmid">38875808</pub-id>
</element-citation></ref><ref id="cit32"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.-H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xuetao</surname><given-names>X.</given-names></name>
</person-group><article-title>Synthesis and biological evaluation of indole derivatives containing thiazolidine-2,4-dione as &#x003b1;-glucosidase inhibitors with antidiabetic activity</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>264</volume><fpage>115957</fpage><ext-link xlink:href="10.1016/j.ejmech.2023.115957" ext-link-type="doi">https://dx.doi.org/10.1016/j.ejmech.2023.115957</ext-link><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115957</pub-id><pub-id pub-id-type="pmid">38029465</pub-id>
</element-citation></ref><ref id="cit33"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Min</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Investigation on the inhibition mechanism and binding behavior of cryptolepine to &#x003b1;-glucosidase and its hypoglycemic activity by multi-spectroscopic method</article-title><source>J. Lumin.</source><year>2024</year><volume>269</volume><fpage>120437</fpage><pub-id pub-id-type="doi">10.1016/j.jlumin.2024.120437</pub-id></element-citation></ref><ref id="cit34"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X.-Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>W.-J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>C.-M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.-Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J.-Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.-T.</given-names></name>
</person-group><article-title>Synthesis and anti-&#x003b1;-glucosidase activity evaluation of betulinic acid derivatives</article-title><source>Arabian J. Chem.</source><year>2023</year><volume>16</volume><fpage>104659</fpage><ext-link xlink:href="10.1016/j.arabjc.2023.104659" ext-link-type="doi">https://dx.doi.org/10.1016/j.arabjc.2023.104659</ext-link><pub-id pub-id-type="doi">10.1016/j.arabjc.2023.104659</pub-id></element-citation></ref><ref id="cit35"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fotopoulos</surname><given-names>I.</given-names></name>
</person-group><article-title>Dimitra Hadjipavlou-Litina, Approaches for the discovery of cinnamic acid derivatives with anticancer potential</article-title><source>Expert Opin. Drug Discovery</source><year>2024</year><volume>19</volume><fpage>1281</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1080/17460441.2024.2387122</pub-id></element-citation></ref><ref id="cit36"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Q.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>H.-Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Quan</surname><given-names>Z.-S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>Q.-K.</given-names></name>
</person-group><article-title>Application of cinnamic acid in the structural modification of natural products: A review</article-title><source>Phytochemistry</source><year>2023</year><volume>206</volume><fpage>113532</fpage><ext-link xlink:href="10.1016/j.phytochem.2022.113532" ext-link-type="doi">https://dx.doi.org/10.1016/j.phytochem.2022.113532</ext-link><pub-id pub-id-type="doi">10.1016/j.phytochem.2022.113532</pub-id><pub-id pub-id-type="pmid">36470328</pub-id>
</element-citation></ref><ref id="cit37"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Su</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Cinnamic acid hybrids as anticancer agents: A mini-review</article-title><source>Arch. Pharm. Chem. Life Sci.</source><year>2022</year><volume>355</volume><fpage>e2200052</fpage><ext-link xlink:href="10.1002/ardp.202200052" ext-link-type="doi">https://dx.doi.org/10.1002/ardp.202200052</ext-link><pub-id pub-id-type="doi">10.1002/ardp.202200052</pub-id><pub-id pub-id-type="pmid">35419808</pub-id>
</element-citation></ref><ref id="cit38"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallikarjuna Reddy</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raul Garcia</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hanuman Reddy</surname><given-names>V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Meier de Andrade</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Camilo Jr</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>R. A. P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>de Lazaro</surname><given-names>S. R.</given-names></name>
</person-group><article-title>Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel tri-substituted thiazole derivatives</article-title><source>Eur. J. Med. Chem.</source><year>2016</year><volume>123</volume><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.07.062</pub-id><pub-id pub-id-type="pmid">27494167</pub-id>
</element-citation></ref><ref id="cit39"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanagaddi</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nannapaneni</surname><given-names>S. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raghupathi</surname><given-names>J. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Katari</surname><given-names>N. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Salakolusu</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Murty</surname><given-names>J. N. S. R. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ranga</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kaliyaperumal</surname><given-names>M.</given-names></name>
</person-group><article-title>Isolation, Identification, and Characterization of Forced Degradation Products of Bosentan by Using Advanced Analytical Techniques</article-title><source>Sep. Sci. plus</source><year>2024</year><volume>7</volume><fpage>e202400194</fpage><ext-link xlink:href="10.1002/sscp.202400194" ext-link-type="doi">https://dx.doi.org/10.1002/sscp.202400194</ext-link><pub-id pub-id-type="doi">10.1002/sscp.202400194</pub-id></element-citation></ref><ref id="cit40"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salakolusu</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Katari</surname><given-names>N. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>G. V. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rendedula</surname><given-names>D. P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ranga</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kaliyaperumal</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raghupathi</surname><given-names>J. K.</given-names></name>
</person-group><article-title>Utilizing cutting-edge analytical techniques for the identification, isolation, and structural characterization of donepezil HCl forced degradation products</article-title><source>Microchem. J.</source><year>2024</year><volume>207</volume><fpage>111665</fpage><ext-link xlink:href="10.1016/j.microc.2024.111665" ext-link-type="doi">https://dx.doi.org/10.1016/j.microc.2024.111665</ext-link><pub-id pub-id-type="doi">10.1016/j.microc.2024.111665</pub-id></element-citation></ref><ref id="cit41"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vunnam</surname><given-names>K. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Katari</surname><given-names>N. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Jeedimalla</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gundla</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raghupathi</surname><given-names>J. K.</given-names></name>
</person-group><article-title>Design, Synthesis, and Biological Evaluation of Novel Heterocyclic Derivatives of 2,4-Thiazolidine Dione as Anti-Cancer Agents</article-title><source>Appl. Res.</source><year>2024</year><fpage>e202400176</fpage><pub-id pub-id-type="doi">10.1002/appl.202400176</pub-id></element-citation></ref><ref id="cit42"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raju bandaru</surname><given-names>L. G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raja Kanuparthy</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Jeedimalla</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nayak</surname><given-names>B. V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raghupathi</surname><given-names>J. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kumar Katari</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gundla</surname><given-names>R.</given-names></name>
</person-group><article-title>Stability indicating RP-HPLC method development and validation for quantification of impurities in gonadotropin-releasing hormone (Elagolix): Robustness study by quality by design</article-title><source>Biomed. Chromatogr.</source><year>2024</year><volume>38</volume><issue>12</issue><fpage>e6036</fpage><ext-link xlink:href="10.1002/bmc.6036" ext-link-type="doi">https://dx.doi.org/10.1002/bmc.6036</ext-link><pub-id pub-id-type="doi">10.1002/bmc.6036</pub-id><pub-id pub-id-type="pmid">39483048</pub-id>
</element-citation></ref><ref id="cit43"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porto</surname><given-names>R. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Porto</surname><given-names>V. A.</given-names></name>
</person-group><article-title>Uncovering the Biological Applications of Cinnamic Acid Derivatives: A Patent Review</article-title><source>Lett. Drug Des. Discovery</source><year>2023</year><volume>21</volume><fpage>2828</fpage><lpage>2837</lpage><ext-link xlink:href="10.2174/0115701808273623231009074241" ext-link-type="doi">https://dx.doi.org/10.2174/0115701808273623231009074241</ext-link><pub-id pub-id-type="doi">10.2174/0115701808273623231009074241</pub-id></element-citation></ref><ref id="cit44"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koczurkiewicz-Adamczyk</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kla&#x0015b;</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gunia-Krzy&#x0017c;ak</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Piska</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Andrysiak</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>St&#x00119;pniewski</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lasota</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>W&#x000f3;jcik-Pszczo&#x00142;a</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Dulak</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Madeja</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>P&#x00119;kala</surname><given-names>E.</given-names></name>
</person-group><article-title>Cinnamic Acid Derivatives as Cardioprotective Agents against Oxidative and Structural Damage Induced by Doxorubicin</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><fpage>6217</fpage><ext-link xlink:href="10.3390/ijms22126217" ext-link-type="doi">https://dx.doi.org/10.3390/ijms22126217</ext-link><pub-id pub-id-type="doi">10.3390/ijms22126217</pub-id><pub-id pub-id-type="pmid">34207549</pub-id>
</element-citation></ref><ref id="cit45"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yazdi</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nafari</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Azadpour</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Alaee</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Moradi</surname><given-names>F. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Choghakhori</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hormozi</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ahmadvand</surname><given-names>H.</given-names></name>
</person-group><article-title>Protective Effects of Cinnamic Acid Against Hyperglycemia Induced Oxidative Stress and Inflammation in HepG2 Cells</article-title><source>Rep. Biochem. Mol. Biol.</source><year>2023</year><volume>12</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.52547/rbmb.12.1.1</pub-id><pub-id pub-id-type="pmid">37724158</pub-id>
</element-citation></ref><ref id="cit46"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Song</surname><given-names>B.</given-names></name>
</person-group><article-title>Novel Cinnamic Acid Derivatives Containing the 1,3,4-Oxadiazole Moiety: Design, Synthesis, Antibacterial Activities, and Mechanisms</article-title><source>J. Agric. Food Chem.</source><year>2021</year><volume>69</volume><fpage>11804</fpage><lpage>11815</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.1c03087</pub-id><pub-id pub-id-type="pmid">34597041</pub-id>
</element-citation></ref><ref id="cit47"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mingoia</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Conte</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Di Rienzo</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pia Dimmito</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Marinucci</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Magi</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Turkez</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cufaro</surname><given-names>M. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Del Boccio</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Di Stefano</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cacciatore</surname><given-names>I.</given-names></name>
</person-group><article-title>Synthesis and Biological Evaluation of Novel Cinnamic Acid-Based Antimicrobials</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><fpage>228</fpage><pub-id pub-id-type="doi">10.3390/ph15020228</pub-id><pub-id pub-id-type="pmid">35215340</pub-id>
</element-citation></ref><ref id="cit48"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chukwuma</surname><given-names>C. I.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mashele</surname><given-names>S. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Swain</surname><given-names>S. S.</given-names></name>
</person-group><article-title>Antidiabetic and antioxidative properties of novel Zn(II)-cinnamic acid complex</article-title><source>Med. Chem.</source><year>2020</year><volume>17</volume><fpage>913</fpage><lpage>925</lpage><ext-link xlink:href="10.2174/1573406416666200929143257" ext-link-type="doi">https://dx.doi.org/10.2174/1573406416666200929143257</ext-link><pub-id pub-id-type="doi">10.2174/1573406416666200929143257</pub-id><pub-id pub-id-type="pmid">32990538</pub-id>
</element-citation></ref><ref id="cit49"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nair</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Preetha Rani</surname><given-names>M. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Salin Raj</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ranjit</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rajankutty</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raghu</surname><given-names>K. G.</given-names></name>
</person-group><article-title>Cinnamic acid is beneficial to diabetic cardiomyopathy via its cardioprotective, anti-inflammatory, anti-dyslipidemia, and antidiabetic properties</article-title><source>J. Biochem. Mol. Toxicol.</source><year>2022</year><volume>36</volume><fpage>e23215</fpage><ext-link xlink:href="10.1002/jbt.23215" ext-link-type="doi">https://dx.doi.org/10.1002/jbt.23215</ext-link><pub-id pub-id-type="doi">10.1002/jbt.23215</pub-id><pub-id pub-id-type="pmid">36117386</pub-id>
</element-citation></ref><ref id="cit50"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>Y.-N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.-Q.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>K.</given-names></name>
</person-group><article-title>Novel cinnamic acid magnolol derivatives as potent &#x003b1;-glucosidase and &#x003b1;-amylase inhibitors: Synthesis, in vitro and in silico studies</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>116</volume><fpage>105291</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.105291</pub-id><pub-id pub-id-type="pmid">34438122</pub-id>
</element-citation></ref><ref id="cit51"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasturi</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Surarapu</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Uppalanchi</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Anireddy</surname><given-names>J. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Dwivedi</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Anantaraju</surname><given-names>H. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Perumal</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sigalapalli</surname><given-names>D. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Babu</surname><given-names>B. N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ethiraj</surname><given-names>K. S.</given-names></name>
</person-group><article-title>Synthesis and &#x003b1;-glucosidase inhibition activity of dihydroxy pyrrolidines</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2017</year><volume>27</volume><fpage>2818</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.04.078</pub-id><pub-id pub-id-type="pmid">28495082</pub-id>
</element-citation></ref><ref id="cit52"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alam</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rehman</surname><given-names>N. U.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ullah</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Halim</surname><given-names>S. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Latif</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zainab</surname></name>
</person-group><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ullah</surname><given-names>O.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Al-Harrasi</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
</person-group><article-title>Bio-Oriented Synthesis of Novel (S)-Flurbiprofen Clubbed Hydrazone Schiff's Bases for Diabetic Management: In Vitro and In Silico Studies</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><fpage>672</fpage><pub-id pub-id-type="doi">10.3390/ph15060672</pub-id><pub-id pub-id-type="pmid">35745591</pub-id>
</element-citation></ref><ref id="cit53"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taha</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>N. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Imran</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wadood</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rahim</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Saad</surname><given-names>S. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>K. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nasir</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis, molecular docking and &#x003b1;-glucosidase inhibition of 5-aryl-2-(6&#x02032;-nitrobenzofuran-2&#x02032;-yl)-1,3,4-oxadiazoles</article-title><source>Bioorg. Chem.</source><year>2016</year><volume>66</volume><fpage>117</fpage><lpage>123</lpage><ext-link xlink:href="10.1016/j.bioorg.2016.04.006" ext-link-type="doi">https://dx.doi.org/10.1016/j.bioorg.2016.04.006</ext-link><pub-id pub-id-type="doi">10.1016/j.bioorg.2016.04.006</pub-id><pub-id pub-id-type="pmid">27149363</pub-id>
</element-citation></ref><ref id="cit54"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taha</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hadiani Ismail</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Imran</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wadood</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rahim</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Riaz</surname><given-names>M.</given-names></name>
</person-group><article-title>Novel thiosemicarbazide&#x02013;oxadiazole hybrids as unprecedented inhibitors of yeast &#x003b1;-glucosidase and in silico binding analysis</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>33733</fpage><lpage>33742</lpage><pub-id pub-id-type="doi">10.1039/c5ra28012e</pub-id></element-citation></ref><ref id="cit55"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viegas-Junior</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Barreiro</surname><given-names>E. J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Fraga</surname><given-names>C. A. M.</given-names></name>
</person-group><article-title>Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes</article-title><source>Curr. Med. Chem.</source><year>2007</year><volume>14</volume><fpage>1829</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.2174/092986707781058805</pub-id><pub-id pub-id-type="pmid">17627520</pub-id>
</element-citation></ref><ref id="cit56"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e9;rub&#x000e9;</surname><given-names>G.</given-names></name>
</person-group><article-title>An overview of molecular hybrids in drug discovery</article-title><source>Expert Opin. Drug Discovery</source><year>2016</year><volume>11</volume><fpage>281</fpage><lpage>305</lpage><ext-link xlink:href="10.1517/17460441.2016.1135125" ext-link-type="doi">https://dx.doi.org/10.1517/17460441.2016.1135125</ext-link><pub-id pub-id-type="doi">10.1517/17460441.2016.1135125</pub-id><pub-id pub-id-type="pmid">26727036</pub-id>
</element-citation></ref><ref id="cit57"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morris</surname><given-names>G. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Huey</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lindstrom</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sanner</surname><given-names>M. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Belew</surname><given-names>R. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Goodsell</surname><given-names>D. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Olson</surname><given-names>A. J.</given-names></name>
</person-group><article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title><source>J. Comput. Chem.</source><year>2009</year><volume>30</volume><fpage>2785</fpage><lpage>2791</lpage><ext-link xlink:href="10.1002/jcc.21256" ext-link-type="doi">https://dx.doi.org/10.1002/jcc.21256</ext-link><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id>
</element-citation></ref><ref id="cit58"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinzi</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rastelli</surname><given-names>G.</given-names></name>
</person-group><article-title>Molecular Docking: Shifting Paradigms in Drug Discovery</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><fpage>4331</fpage><ext-link xlink:href="10.3390/ijms20184331" ext-link-type="doi">https://dx.doi.org/10.3390/ijms20184331</ext-link><pub-id pub-id-type="doi">10.3390/ijms20184331</pub-id><pub-id pub-id-type="pmid">31487867</pub-id>
</element-citation></ref><ref id="cit59"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daina</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Michielin</surname><given-names>O.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zoete</surname><given-names>V.</given-names></name>
</person-group><article-title>iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach</article-title><source>J. Chem. Inf. Model.</source><year>2014</year><volume>54</volume><fpage>3284</fpage><lpage>3301</lpage><pub-id pub-id-type="doi">10.1021/ci500467k</pub-id><pub-id pub-id-type="pmid">25382374</pub-id>
</element-citation></ref><ref id="cit60"><mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>T. P.</given-names></name>
</person-group>, <person-group person-group-type="author"><name><surname>Sanchez-Covarubias</surname><given-names>L.</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Tome</surname><given-names>M. E.</given-names></name></person-group>, <article-title>P-glycoprotein Trafficking as a Therapeutic Target to Optimize CNS Drug Delivery</article-title>, <source>Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders</source>, <year>2014</year>, pp. 25&#x02013;44, <pub-id pub-id-type="doi">10.1016/bs.apha.2014.06.009</pub-id></mixed-citation></ref><ref id="cit61"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fromm</surname><given-names>M. F.</given-names></name>
</person-group><article-title>P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs</article-title><source>Int. J. Clin. Pharmacol. Ther.</source><year>2000</year><volume>38</volume><fpage>69</fpage><lpage>74</lpage><ext-link xlink:href="10.5414/cpp38069" ext-link-type="doi">https://dx.doi.org/10.5414/cpp38069</ext-link><pub-id pub-id-type="doi">10.5414/CPP38069</pub-id><pub-id pub-id-type="pmid">10706193</pub-id>
</element-citation></ref><ref id="cit62"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pistia-Brueggeman</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hollingsworth</surname><given-names>R. I.</given-names></name>
</person-group><article-title>A preparation and screening strategy for glycosidase inhibitors</article-title><source>Tetrahedron</source><year>2001</year><volume>57</volume><fpage>8773</fpage><lpage>8778</lpage><ext-link xlink:href="10.1016/s0040-4020(01)00877-8" ext-link-type="doi">https://dx.doi.org/10.1016/s0040-4020(01)00877-8</ext-link><pub-id pub-id-type="doi">10.1016/S0040-4020(01)00877-8</pub-id></element-citation></ref><ref id="cit63"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhatia</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Arora</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Arora</surname><given-names>S.</given-names></name>
</person-group><article-title>In vitro evaluation of the &#x003b1;-glucosidase inhibitory potential of methanolic extracts of traditionally used antidiabetic plants</article-title><source>BMC Compl. Alternative Med.</source><year>2019</year><volume>19</volume><fpage>74</fpage><ext-link xlink:href="10.1186/s12906-019-2482-z" ext-link-type="doi">https://dx.doi.org/10.1186/s12906-019-2482-z</ext-link><pub-id pub-id-type="doi">10.1186/s12906-019-2482-z</pub-id><pub-id pub-id-type="pmid">30909900</pub-id>
</element-citation></ref><ref id="cit64"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daina</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Michielin</surname><given-names>O.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zoete</surname><given-names>V.</given-names></name>
</person-group><article-title>SwissADME: a Free web Tool to Evaluate pharmacokinetics, drug-likeness and Medicinal Chemistry Friendliness of Small Molecules</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28127051</pub-id>
</element-citation></ref></ref-list></back></article>